biolitec AG continues strong revenue and profit growth in the first half of the year - EBIT growth of 23 % up to Euro 3.0 million - BPH laser were placed in the market as planned

Again record profits in the first six months of fiscal year 2007/2008
– Innovative laser therapy LIFE ™ for the treatment of enlarged
prostate (BPH) and revolutionary vein treatment pro-cedure ELVeS ™
are biggest revenue driver – Group turnover increases by 12 % up to
Euro 19.1 million

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

companies/pharmaceuticals/stock market

Jena (euro adhoc) - Jena, February 29th 2008 - biolitec AG, Jena,
listed in the Prime Standard of the Frankfurt stock exchange (ISIN
DE0005213409) managed to in-crease consolidated revenues by 12 % to
Euro 19.1 million during the first six months ending December 31,
2007 (previous year: Euro 17.1 million). The gross profit amounted
Euro 13.0 million (previous year: Euro 11.7 mil-lion). The earnings
before interest and taxes (EBIT) increased up to Euro 3.0 million
(plus 23 %).

Thanks to the sales increases especially in BPH and aesthetic
treatment systems of biolitec AG, for example ELVeS™, the net income
amounted Euro 2.2 million (previous year: Euro 1.9 million). With new
LIFE™ laser therapy using the EVOLVE ™ urology laser, biolitec AG
establishes an un-complicated and effective procedure for a new and
innovative medical care for patients with benign prostate hyperplasia
in Germany and the United States. LIFE™ laser therapy is already
available in more than 20 treatment centres in Germany. Inpatient
treatment costs are reimbursed by statutory health insurance since
2008. With Endo Laser Vein System - ELVeS™ bio-litec also has created
a new worldwide standard for the treatment of venous insufficiency.

Second quarter revenue increase was modest (from Euro 9.7 million up
to Euro 9.8 million) due to a shifting effect to direct sales from
distribu-tors/marketing partners. Dr. Wolfgang Neuberger, CEO of
biolitec AG comments: "We expect that the attractive reimbursement
rates for BPH treatments using laser adopted in January 2008 will
speed up the adoption of the new therapy in Germany in particular.
While laser placements pro-ceeded at a good rate in the US, closings
were behind expectations. We expect to reach our BPH market share
goal of 40 % in the US within 12 to 24 months".

With Euro 3.2 million (17 % of sales) in the first six months of the
business year, R&D expenditures of biolitec remain at a high level,
ensuring the groups long term growth and profitability. The strongest
increases with 7 % respectively 23 % were achieved in biolitec´s
traditional fields´ fibers/probes and lasers. North American revenues
increased by 23 % in the first six months, accounting for 51 % of
total sales.

For the course of the year biolitec expects an ongoing positive
business development. The current growth is mainly driven by the
strong demand for the company´s BPH treatment, the new ELVeS™
PainLess vein therapy and aesthetic therapies in general. The
photodynamic therapy using the cancer drug Foscan® shows steadily to
be a successful development. An important milestone for Foscan® was
the approval of low-dose Foscan® vials. In December 2007 the cancer
drug has also received approval of the regulatory authority in
Argentina. "With this approval we can now work to-gether with our
local distributor to start the sales and marketing activities in
Argentina", added Dr. Neuberger.

About biolitec biolitec is the only supplier for photodynamic therapy
worldwide that offers all rele-vant core competencies -
photosensitizers, lasers and optical fibers. Besides minimal invasive
laser treatments and the oncology business biolitec has success-fully
developed competencies in the field of aesthetics. biolitec is listed
in the Prime Standard under ISIN DE0005213409. For more information:
www.biolitec.com.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: BioLitec AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Press contact

Jörn Gleisner

Phone : +49 (0) 69 / 959083-20

Fax : +49 (0) 69 / 959083-99

E-mail: j.gleisner@financial-relations.de

Branche: Pharmaceuticals
ISIN: DE0005213409
WKN: 521340
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade